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Objectives The ENDEAVOR IV (Randomized Comparison of Zotarolimus-Eluting and Paclitaxel-Eluting Stents in Patients with
Coronary Artery Disease) trial evaluated the safety and efficacy of the zotarolimus-eluting stent (ZES) compared
with the paclitaxel-eluting stent (PES).
Background First-generation drug-eluting stents have reduced angiographic and clinical restenosis, but long-term safety re-
mains controversial. A second-generation drug-eluting stent, which delivers zotarolimus, a potent antiprolifera-
tive agent, via a biocompatible phosphorylcholine polymer on a cobalt alloy thin-strut stent has shown promising
experimental and early clinical results.
Methods This is a prospective, randomized (1:1), single-blind, controlled trial comparing outcomes of patients with single
de novo coronary lesions treated with ZES or PES. The primary end point was noninferiority of 9-month target
vessel failure defined as cardiac death, myocardial infarction, or target vessel revascularization.
Results Among a total of 1,548 patients assigned to ZES (n  773) or PES (n  775), at 9 months, ZES was noninferior
to PES with rates of target vessel failure 6.6% versus 7.1%, respectively (pnoninferiority  0.001). There were fewer
periprocedural myocardial infarctions with ZES (0.5% vs. 2.2%; p  0.007), whereas at 12 months, there were
no significant differences between groups in rates of cardiac death, myocardial infarction, target vessel revascu-
larization, or stent thrombosis. Although incidence of 8-month binary angiographic in-segment restenosis was
higher in patients treated with ZES versus PES (15.3% vs. 10.4%; p  0.284), rates of 12-month target lesion
revascularization were similar (4.5% vs. 3.2%; p  0.228), especially in patients without planned angiographic
follow-up (3.6% vs. 3.2%; p  0.756).
Conclusions These findings demonstrate that ZES has similar clinical safety and efficacy compared with PES in simple and
medium complexity single de novo coronary lesions. (ENDEAVOR IV Clinical Trial; NCT00217269) (J Am Coll
Cardiol 2010;55:543–54) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.067setts; Beth Israel Deaconess Medical Center, Boston, Massachusetts; ¶Elyria
Memorial Hospital, Elyria, Ohio; #Lubbock Heart Hospital, Lubbock, Texas;rom the *Columbia University Medical Center and the Cardiovascular Research
oundation, New York, New York; †St. Joseph Hospital, Syracuse, New York;
Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts;
Caritas Cardiovascular Center, St. Elizabeth’s Medical Center, Boston, Massachu-
**Methodist Hospital, Houston, Texas; ††Mother Frances Health System, Tyler,
Texas; ‡‡Anderson Medical Center, Anderson, South Carolina; §§Emory University,
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eluting stents (DES) in the
U.S. more than 5 years ago,
angiographic restenosis and re-
peat revascularization proce-
dures after percutaneous coro-
nary interventions have been
significantly reduced for both
simple (“on-label”) and com-
plex (“off-label”) lesions (1–5).
Safety concerns, however, have
been raised for both sirolimus-
eluting stents (SES) (Cordis Corpo-
ration, Warren, New Jersey) and
paclitaxel-eluting stents (PES) (Bos-
ton Scientific, Natick, Massachu-
setts), focusing on a small increase in
stent thrombosis occurring longer
than 1 year after the index proce-
dure (6–8). Consequently, treat-
ment practices have shifted, result-
ing in a more selective use of DES,
extended dual antiplatelet therapy
(DAPT) regimens (to 1 year or
onger), and concerns about premature cessation of DAPT due
o either patient noncompliance or intervening medical prob-
ems (9,10).
See page 555
The design features of an “optimally safe” DES remain
lusive, although most observers agree that impaired early
nd late healing responses, perhaps associated with cer-
tlanta, Georgia;  Heart Center of Indiana, Indianapolis, Indiana; ¶¶Washington
ospital, Fremont, California; ##Stanford University, Stanford, California;
**Medtronic CardioVascular, Santa Rosa, California; †††Scripps Clinic, La Jolla,
alifornia; and the ‡‡‡Presbyterian Hospital, Charlotte, North Carolina. The
NDEAVOR IV clinical trial was funded by Medtronic CardioVascular, Santa Rosa,
alifornia. Dr. Leon has served as a consultant to Volcano Corporation, Abbott Vascular,
oston Scientific, Cordis, and Medtronic, Inc. Dr. Mauri has served as a consultant to
bbott, Boston Scientific, Cordis, and Medtronic, Inc. Dr. Popma has received research
rants from Cordis, Boston Scientific, Medtronic, Abbott Vascular, Biosensors, and ev3;
as served as a consultant for Medtronic, Boston Scientific, Cordis, Abbott Vascular, and
illy; and has served as a speaker for Pfizer, Bristol-Myers Squibb, Sanofi, Lilly, Boston
cientific, Medtronic, Cordis, and The Medicines Co. Dr. O’Shaughnessy has received
esearch grants from Medtronic, Inc. and Boston Scientific, and is on the advisory board
nd Speakers’ Bureau of Boston Scientific. Dr. Overlie has served as a clinical investigator
or Abbott Vascular, Boston Scientific, Cordis, and Medtronic, Inc. Dr. Solomon is a
egistered speaker for the Medtronic Corporation. Dr. Douglas is a research investigator
or Medtronic, Cordis, Boston Scientific, St. Jude, and Abbott. Dr. Caputo is a consultant
o Boston Scientific and Cordis, and is on the Speakers’ Bureau of Medtronic and Abbott.
r. Kirtane has served as a consultant and speaker for Medtronic CardioVascular, Abbott
ascular, and Boston Scientific. Dr. Fitzgerald has served as a consultant for Abbott,
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laxoSmithKline, XTENT, ATI, Volcano Corporation, Novadaq, AorTx, CardioMind,
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upport and consulting honoraria from Medtronic CardioVascular, Inc. and Cordis
orporation.
Abbreviations
and Acronyms
ARC  Academic Research
Consortium
DAPT  dual antiplatelet
therapy
DES  drug-eluting stent(s)
DS  diameter stenosis
IVUS  intravascular
ultrasound
MI  myocardial infarction
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularization
TVF  target vessel failure
TVR  target vessel
revascularization
ZES  zotarolimus-eluting
stent(s)r
Manuscript received May 19, 2009; revised manuscript received August 26, 2009,
ccepted August 30, 2009.ain biostable polymers, may be partially causative (11,12).
he zotarolimus-eluting stent (ZES) (Medtronic CardioVas-
ular, Santa Rosa, California) combines a more rapid elution
rofile of the antiproliferative drug zotarolimus with a
hinner, more biocompatible phosphorylcholine polymer
laced on a cobalt alloy thin-strut stent. ZES have been
linically tested in a first-human-use study with extended
ollow-up (13,14), a double-blind randomized trial versus
are-metal stents (15), and a small randomized trial versus
ES (16). These studies have indicated that ZES, when
ompared with bare-metal stents (15), had an advantageous
afety profile and reduced target lesion revascularization
TLR) despite a somewhat higher angiographic late loss
han observed with SES and PES (1–3,16). The purpose of
he current trial was to compare ZES with commonly used
ES in a large randomized trial, emphasizing clinical end
oints, to limit the impact of systematic angiographic
ollow-up on repeat revascularization decisions.
ethods
tudy design and patient population. The ENDEAVOR
V (Randomized Comparison of Zotarolimus-Eluting and
aclitaxel-Eluting Stents in Patients with Coronary Artery
isease) trial was a prospective, multicenter, single-blinded,
andomized, controlled clinical trial that compared clinical
nd angiographic outcomes between patients treated with
ES and patients treated with PES. Consecutive adult
atients with clinical evidence of ischemic coronary disease
r a positive functional study were enrolled at 80 centers in
he U.S.
Key clinical exclusion criteria included recent acute myocar-
ial infarction (MI), another planned percutaneous coronary
ntervention within the next 30 days or previous percutaneous
oronary intervention in the target vessel within the previous 9
onths, recent stroke or transient ischemic attack, left ventric-
lar ejection fraction less than 30%, and contraindication to
APT (aspirin and a thienopyridine).
Angiographic requirements were the presence of a single
e novo native coronary lesion with a diameter stenosis
DS) of at least 50% but 100% by visual estimate,
eference vessel diameter 2.5 and 3.5 mm, and lesion
ength 27 mm. A target vessel with evidence of thrombus
r excessive tortuosity or a target lesion that was in a left
ain or an ostial location, or with severe calcification, or at
bifurcation involving a side branch 2.0 mm in diameter
ere excluded.
The institutional review board at each site approved the
rotocol, and each eligible patient provided written, in-
ormed consent before the index procedure.
tudy device. The Endeavor ZES (Medtronic) consists
f a cobalt-based alloy stent with a phosphorylcholine
oating that releases the drug zotarolimus. The synthetic
hosphorylcholine drug carrier is composed of an outer
hospholipid portion that mimics the outer membrane of
ed blood cells to provide biocompatibility and an inner
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February 9, 2010:543–54 12-Month Outcomes From the ENDEAVOR IV Trialydrophobic region to confer stability and adhesion to
he stent surface (17). A confluent coating of phospho-
ylcholine on bare-metal stents reduces thrombogenicity
n in vitro models (18). Zotarolimus (ABT-578) is a
etrazole ring containing macrocyclic lactone analogue of
irolimus and is the first cytostatic agent developed
xclusively for delivery from a DES to prevent restenosis
19). The phosphorylcholine coating thickness is approx-
mately 4 m and the concentration of zotarolimus is 10
g/mm stent length. The ZES formulation results in
apid drug elution from the stent surface (80% in 1
eek and 95% in 2 weeks). In animal studies, ZES were
ssociated with less platelet adhesion, improved early
ealing responses compared with other first-generation
ES, and reduced neointimal area (20,21).
The TAXUS Express PES (Boston Scientific) consists of
316L surgical grade stainless steel Express stent, a Trans-
ute (Boston Scientific) polymer carrier, and paclitaxel
oaded in a concentration of 1 g/mm2 in a slow release
ormulation.
andomization, implantation procedure, adjunct phar-
acology, and follow-up. Patients were stratified by dia-
etic status and clinical site and were randomized (using an
nteractive Voice Response System) in a 1:1 manner to
eceive either ZES or PES. Diabetes was defined as treat-
Figure 1 Patient Disposition and Follow-Up
Randomization, angiographic follow-up, and clinical follow-up. mo  month; QCA ent for diabetes mellitus with insulin, oral antidiabetic
gents, or a modified diet.
Target lesions were pre-treated using standard balloon
ngioplasty, followed by stent implantation and post-
ilation (as needed) to achieve a final lumen DS of
10%. Patients were treated with 75 mg of aspirin within
4 h before the procedure, which was continued indefi-
itely. All patients received a loading dose of clopidogrel
f at least 300 mg followed by 75 mg/day for at least 6
onths. Continuation of clopidogrel beyond 6 months
as at the operator’s discretion. During the procedure,
ivalirudin or unfractionated heparin (to maintain an
ctivated clotting time 250 s) was administered. Plate-
et glycoprotein IIb/IIIa receptor inhibitors were used at
he discretion of the operator.
Following the interventional procedure, patients were
ssessed at 30 days; 6, 9, and 12 months; and yearly
hereafter up to 5 years after the procedure. Patients in the
ngiographic and intravascular ultrasound (IVUS) subgroups
ere evaluated at 8 months after the procedure.
ata management and analysis. An independent data
anagement organization (Harvard Clinical Research
nstitute, Boston, Massachusetts) collected and managed
ll data analyses. All authors had full access to the
atabase and analysis upon which this manuscript is
titative coronary angiography.quan
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12-Month Outcomes From the ENDEAVOR IV Trial February 9, 2010:543–54ased. An independent clinical events committee,
linded to the study stent identity, adjudicated all pri-
ary and secondary end point events. An independent
ata safety monitoring board, composed of 4 independent
hysicians and 1 biostatistician blinded to study treat-
ent, was responsible for regular review of the clinical
afety data and could recommend study discontinuation
r modification.
nd points and definitions. The primary clinical end
oint was target vessel failure (TVF), defined as the
omposite of cardiac death, MI, or clinically driven target
essel revascularization (TVR) at 9 months after the
rocedure. Secondary clinical end points were acute
evice, lesion, and procedure success and major adverse
ardiac event, defined as death, MI, or clinically driven
LR. Secondary angiographic end points were in-
egment and in-stent late lumen loss and binary restenosis.
he IVUS end points at follow-up were neointima hyperplasia
olume, percent volume obstruction, stent strut apposition to
he vessel wall, and positive vessel remodeling.
Stent thrombosis as defined by the clinical protocol required
of the following: 1) coronary symptoms and target vessel
ngiographic confirmation of thrombus or occlusion; 2) patho-
aseline Clinical and Angiographic Characteristics of the Study PoTable 1 Baseline Clinical and Angiographic Characteristics of t
Patient demographics
Age, yrs
Men
Diabetes
Hypertension
Hyperlipidemia
History of smoking
Prior myocardial infarction
Prior percutaneous coronary intervention
Prior coronary bypass surgery
Angina
Stable
Unstable
Myocardial infarction
CCS class III or IV
Angiographic characteristics
Target vessel
Left anterior descending
Left circumflex
Right coronary
Type B2/C lesion
Number of diseased, native, major epicardial coronary vessels (50% stenosed)
Single
Double
Triple
Left ventricular ejection fraction, %
Reference vessel diameter, mm
Lesion length, mm
Minimal lumen diameter, mm
Diameter stenosis, %alues are presented as % (n/total) or mean  SD (n).
CCS  Canadian Cardiovascular Society angina class; PES  paclitaxel-eluting stent(s); ZES  zotaroliogic confirmation of acute thrombosis in the target vessel; 3)
nexplained death within 30 days; or 4) target vessel MI
ithout angiographic confirmation of thrombosis or other
dentified culprit lesions within 30 days. Patients with inter-
ening TLR events were excluded and protocol-defined stent
hrombosis was assessed within 24 h (acute), at 1 to 30 days
subacute), and after 30 days following stent placement (late).
tent thrombosis (both early and late) was also adjudicated by
subcommittee of the clinical events committee blinded to
tudy stent identity and according to the definitions proposed
y the Academic Research Consortium (ARC) (22).
ngiography and IVUS core laboratories. Coronary an-
iograms were obtained at baseline in all patients, and at 8
onths after the procedure in the first 328 consecutive
atients enrolled and assigned to routine angiographic
ollow-up and in any patient who received multiple stents.
ll angiograms were evaluated by reviewers blinded to the
tudy stent, by an independent core laboratory (Brigham
nd Women’s Angiographic Core Laboratory, Boston,
assachusetts).
All patients in the angiographic subgroup underwent
VUS imaging at 8 months, which was evaluated by
eviewers blinded to the study stent at an independent IVUS
iontudy Population
ZES PES p Value
63.5 11.1 (773) 63.6 11.0 (775) 0.930
66.9% (517/773) 68.5% (531/775) 0.514
31.2% (241/773) 30.5% (236/775) 0.783
79.4% (614/773) 82.6% (640/775) 0.120
81.4% (629/773) 84.8% (657/775) 0.078
62.6% (479/765) 60.4% (462/765) 0.401
21.1% (161/764) 23.2% (176/759) 0.324
28.2% (218/773) 29.5% (229/775) 0.575
9.8% (76/773) 8.4% (65/775) 0.332
0.367
45.6% (281/616) 47.9% (292/609)
51.6% (318/616) 49.9% (304/609)
2.8% (17/616) 2.1% (13/609)
50.3% (309/614) 47.9% (292/610) 0.392
0.791
42.2% (326/772) 41.5% (321/774)
26.9% (208/772) 26.1% (202/774)
30.8% (238/772) 32.4% (251/774)
69.6% (537/772) 70.9% (549/774) 0.358
0.485
54.9% (424/772) 57.2% (443/774)
28.6% (221/772) 26.1% (202/774)
16.5% (127/772) 16.7% (129/774)
57.3 9.9 (760) 57.5 10.3 (753) 0.745
2.73 0.47 (772) 2.70 0.46 (774) 0.197
13.41 5.67 (771) 13.80 6.09 (773) 0.199
0.96 0.40 (772) 0.93 0.40 (774) 0.149
64.83 13.29 (772) 65.68 13.10 (774) 0.204pulathe Smus-eluting stent(s).
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February 9, 2010:543–54 12-Month Outcomes From the ENDEAVOR IV Trialore laboratory (Cardiovascular Core Analysis Laboratory,
tanford University, Palo Alto, California).
tatistical methods. This randomized study was de-
igned to determine if the primary end point (TVF at 9
onths) of ZES was noninferior to PES. The sample size
stimation was based on a noninferiority test using the
arrington-Manning approach at alpha  0.05 (1-sided)
ignificance level with 84% statistical power to reject the
ull hypothesis of inferiority (23). Assuming an expected
VF rate for ZES and PES to be 7.6%, a noninferiority
argin of 3.8% with at least 90% clinical follow-up and
:1 randomization, a total sample size of 1,548 enrolled
atients was required.
In-segment late lumen loss at 8 months comparing
ES and PES was a secondary powered noninferiority
ngiographic end point. The estimated sample size for
he angiographic subset was based on a 2-sample t test at
lpha  0.05 (1-sided) significance level with 90%
tatistical power to reject the null hypothesis of inferior-
ty. Assuming a true equivalence of the means between
he 2 groups, a noninferiority margin of 0.2 mm, with a
ommon SD of 0.55 mm, 80% angiographic follow-up
ate, and 1:1 randomization, a total sample size of 328
atients was required for the angiographic substudy.
For other secondary clinical and angiographic out-
omes, the 2-sample t test (2-sided) was used to compare
ontinuous variables, and Fisher exact test was used to
ompare binary variables. Kaplan-Meier cumulative inci-
ence estimates were used to analyze outcome events,
hich were compared between treatment groups using
he log-rank test.
To identify the predictors of TLR and TVF at 12 months,
stepwise multivariable logistic regression analysis was per-
Procedural Characteristics and Angiographic ReTable 2 Procedural Characteristics and Ang
Z
Procedural characteristics
Number of stents 1.07
Stent length, mm 21.12
Maximum stent diameter, mm 3.04
Maximum inflation pressure, atm 13.28
Glycoprotein IIb/IIIa inhibitors used 26.8% (2
Procedural angiographic results
Minimum lumen diameter, mm
In-stent 2.62
In-segment 2.22
Diameter stenosis, %
In-stent 5.50
In-segment 20.47
Acute gain, mm
In-stent 1.66
In-segment 1.26
Device success 97.3% (7
Lesion success 99.6% (7
Procedure success 98.7% (7Values are presented as mean  SD (n) or % (n/total).
Abbreviations as in Table 1.ormed for overall patients and for ZES and PES patient
roups separately. The level of significance to enter and stay in
he model was set at 0.05. Appropriate candidate variables were
ntered into the model, including assignment to angiographic
ollow-up and ZES versus PES for the overall patients.
To explore whether the treatment effects of TVF and
LR were consistent across important subgroups, logistic
egression analysis was performed to test the interaction
mong the treatment assignment and the subsets.
All analyses were performed with SAS software (version
.2 or higher, SAS Institute, Cary, North Carolina).
esults
atient enrollment and baseline characteristics. Between
pril 11, 2005, and June 27, 2006, a total of 1,548
atients were enrolled at 80 clinical sites in the U.S.
ZES: n  773, PES: n  775) (Fig. 1). Clinical
ollow-up at 30 days was obtained in 770 ZES and 773
ES patients (99.6% and 99.7%, respectively). Clinical
ollow-up for ZES patients was 98.3% at 9 months and
7.5% at 12 months, and for PES patients was 97.5% at
months and 96.9% at 12 months. Angiographic
ollow-up at 8 months was obtained in 144 ZES patients
87.8% of eligible) and in 135 PES patients (82.3% of
ligible).
Baseline clinical characteristics for ZES and PES cohorts
ere well-balanced (Table 1). For the overall study popu-
ation, mean age was 63.5 years, 67.7% were male, and
0.8% were diabetic. Approximately one-half of the patients
ad stable angina, unstable angina, or Canadian Cardiovas-
ular Society class III/IV angina.
phic Results
PES p Value
63) 1.12 0.38 (762) 0.007
63) 21.30 8.15 (761) 0.666
63) 3.04 0.38 (761) 0.804
62) 13.96 2.79 (765) 0.001
73) 26.7% (207/775) 1.000
63) 2.61 0.44 (763) 0.703
70) 2.19 0.50 (772) 0.196
63) 5.01 10.49 (763) 0.348
70) 20.97 11.12 (772) 0.344
63) 1.68 0.47 (763) 0.425
70) 1.26 0.51 (772) 0.937
72) 97.9% (757/773) 0.412
70) 99.2% (766/772) 0.507
70) 96.8% (747/772) 0.015sultsiogra
ES
0.32 (7
7.94 (7
0.38 (7
2.61 (7
07/7
0.43 (7
0.47 (7
9.61 (7
9.54 (7
0.48 (7
0.50 (7
51/7
67/7
60/7
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12-Month Outcomes From the ENDEAVOR IV Trial February 9, 2010:543–54Target vessel location was in the left anterior descending
oronary in 41.8% of patients and 56.1% had single-vessel
isease (Table 1). Mean reference vessel diameter for all
atients was 2.72 mm, mean lesion length was 13.60 mm,
nd pre-procedure percent DS was 65.3%.
rocedural results and angiographic outcomes. Although
tent length and stent diameter were similar between
ES and PES patients, the numbers of stents per lesion
nd maximum inflation pressures were lower in ZES
atients (Table 2). Post-procedural minimal lumen di-
meter, percent DS, and acute gain were similar among
ES and PES treatment arms (Table 2). Procedure
uccess was significantly higher for ZES when compared
ith PES (98.7% vs. 96.8%, p  0.015).
In those patients assigned to angiographic follow up at 8
onths, there were statistically significant differences in min-
mal lumen diameter, percent DS, and late lumen loss (both
n-stent and in-segment) favoring PES (Table 3). The pow-
red secondary end point, in-segment late lumen loss, was 0.36
m for ZES and 0.23 mm for PES (pnoninferiority  0.089).
inary angiographic in-stent restenosis was 13.3% for ZES
nd 6.7% for PES (p 0.075), and in-segment restenosis was
5.3% for ZES and 10.4% for PES (p  0.284) (Table 3).
VUS results. Quantitative IVUS imaging was performed at
months follow-up in 164 ZES patients and 164 PES
atients. Neointimal volume was 24.14 mm3 for ZES and
Angiographic Outcomes at 8 MonthsTable 3 Angiographic Outcomes at 8 Month
ZES
No. of lesions 144
Reference vessel diameter, mm 2.65 0.47
Minimum lumen diameter, mm
In-stent 1.95 0.61
In-segment 1.80 0.55
Diameter stenosis, %
In-stent 26.41 19.7
In-segment 32.28 17.0
Late loss, mm
In-stent 0.67 0.49
In-segment 0.36 0.47
Binary restenosis
In-stent 13.3% (19/
In-segment 15.3% (22/
Values are presented as mean  SD (n) or % (n/total).
Abbreviations as in Table 1.
IVUS Findings at 8 MonthsTable 4 IVUS Findings at 8 Months
ZES (n  164
Neointimal volume, mm3 24.14 19.38 (7
Volume obstruction, % 15.72 10.40 (7
Incomplete apposition
Post-procedure 12.5% (17/136
Persistent 8.5% (9/106)
Resolved 3.8% (4/106)
Late acquired 0.9% (1/106)Values are presented as mean  SD (n) or % (n/total).
IVUS  intravascular ultrasound; other abbreviations as in Table 1.4.88 mm3 for PES (p  0.002) and percent volume obstruc-
ion was 15.72 for ZES and 9.88 for PES (p  0.001).
ncomplete stent strut apposition immediately after the proce-
ure was similar in both groups and late acquired incomplete
pposition was present in 1 ZES patient (0.9%) and 3 PES
atients (3.2%; p  0.346) (Table 4).
0-day clinical outcomes. At 30 days, there were fewer
on–Q-wave MIs in patients receiving ZES versus pa-
ients receiving PES (0.5% vs. 2.2%, p  0.007) (Table 5).
imilarly, ZES patients had reduced rates of cardiac
eath or MI, TVF, and major adverse cardiac events (p 
.042, p  0.010, and p  0.019, respectively). There
ere no significant differences between treatment arms
or death, cardiac death, and stent thrombosis (protocol
efinition and ARC definition) (Table 5).
- and 12-month clinical outcomes. The primary end
oint, TVF at 9 months, was similar when comparing
ES and PES patients (6.6% for ZES and 7.1% for PES,
noninferiority  0.001) (Table 6, Fig. 2A). At 9 and 12
onths, there were trends showing fewer non–Q-wave
Is with ZES compared with PES (p  0.118 and p 
.095, respectively) (Table 6). There were no significant
ifferences at 9 or 12 months between treatment arms for
eath, cardiac death, any MI, and major adverse cardiac
vents (Table 6, Fig. 2B).
PES p Value
135
2.68 0.45 (135) 0.635
2.25 0.61 (135) 0.001
1.98 0.56 (135) 0.008
) 16.09 17.99 (135) 0.001
) 26.61 15.52 (135) 0.004
0.42 0.50 (135) 0.001
0.23 0.45 (135) 0.023
6.7% (9/135) 0.075
10.4% (14/135) 0.284
PES (n  164) p Value
14.88 16.62 (77) 0.002
9.88 9.24 (77) 0.001
11.8% (15/127) 1.000
10.5% (10/95) 0.638
2.1% (2/95) 0.686
3.2% (3/95) 0.346s
(144)
(143)
(144)
4 (143
2 (144
(142)
(143)
143)
144))
4)
4)
)
CV
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ZES PES p Value
Death (all) 0.3% (2/770) 0.0% (0/773) 0.249
Cardiac 0.1% (1/770) 0.0% (0/773) 0.499
Noncardiac 0.1% (1/770) 0.0% (0/773) 0.499
Myocardial infarction (all) 0.8% (6/770) 2.3% (18/773) 0.022
Q-wave 0.3% (2/770) 0.1% (1/773) 0.624
Non–Q-wave 0.5% (4/770) 2.2% (17/773) 0.007
Death or myocardial infarction 1.0% (8/770) 2.3% (18/773) 0.073
Cardiac death or myocardial infarction 0.9% (7/770) 2.3% (18/773) 0.042
Stent thrombosis
Protocol definition
Acute (1 day) 0.0% (0/770) 0.0% (0/773)
Subacute (1–30 days) 0.4% (3/770) 0.1% (1/773) 0.374
Acute and subacute 0.4% (3/770) 0.1% (1/773) 0.374
ARC definition (early)
Definite 0.3% (2/770) 0.1% (1/773) 0.624
Probable 0.1% (1/770) 0.0% (0/773) 0.499
Definite and probable 0.4% (3/770) 0.1% (1/773) 0.374
Target lesion revascularization 0.4% (3/770) 0.8% (6/773) 0.507
Target vessel revascularization 0.4% (3/770) 0.9% (7/773) 0.342
Nontarget lesion, target vessel revascularization 0.0% (0/770) 0.3% (2/773) 0.500
Target vessel failure 1.0% (8/770) 3.0% (23/773) 0.010
Major adverse cardiac events 1.2% (9/770) 3.0% (23/773) 0.019Values are presented as % (n/total).
ARC  Academic Research Consortium; other abbreviations as in Table 1.linical Outcomes at 9 and 12 MonthsTable 6 Clinical Outcomes at 9 and 12 Months
9-Month Outcomes 12-Month Outcomes
ZES (n  773) PES (n  775) p Value ZES (n  773) PES (n  775) p Value
Death (all) 0.7% (5/760) 0.8% (6/756) 0.773 1.1% (8/754) 1.1% (8/751) 1.000
Cardiac 0.4% (3/760) 0.3% (2/756) 1.000 0.5% (4/754) 0.5% (4/751) 1.000
Noncardiac 0.3% (2/760) 0.5% (4/756) 0.451 0.5% (4/754) 0.5% (4/751) 1.000
Myocardial infarction (all) 1.4% (11/760) 2.4% (18/756) 0.195 1.6% (12/754) 2.7% (20/751) 0.158
Q-wave 0.3% (2/760) 0.1% (1/756) 1.000 0.3% (2/754) 0.1% (1/751) 1.000
Non–Q-wave 1.2% (9/760) 2.2% (17/756) 0.118 1.3% (10/754) 2.5% (19/751) 0.095
Death or myocardial infarction 2.1% (16/760) 3.2% (24/756) 0.204 2.7% (20/754) 3.7% (28/751) 0.244
Cardiac death or myocardial infarction 1.8% (14/760) 2.6% (20/756) 0.304 2.1% (16/754) 3.2% (24/751) 0.204
Stent thrombosis
Protocol definition
Acute (1 day) 0.0% (0/760) 0.0% (0/756) 1.000 0.0% (0/754) 0.0% (0/751) 1.000
Subacute (1–30 days) 0.4% (3/760) 0.1% (1/756) 0.625 0.4% (3/754) 0.1% (1/751) 0.625
Late (30 days to 1 year) 0.4% (3/760) 0.0% (0/756) 0.250 0.4% (3/754) 0.0% (0/751) 0.250
Any 0.8% (6/760) 0.1% (1/756) 0.124 0.8% (6/754) 0.1% (1/751) 0.124
ARC definition (early and late)
Definite 0.7% (5/760) 0.1% (1/756) 0.218 0.7% (5/754) 0.1% (1/751) 0.218
Probable 0.3% (2/760) 0.0% (0/756) 0.500 0.3% (2/754) 0.0% (0/751) 0.500
Possible 0.3% (2/760) 0.3% (2/756) 1.000 0.4% (3/754) 0.4% (3/751) 1.000
Definite and probable 0.9% (7/760) 0.1% (1/756) 0.070 0.9% (7/754) 0.1% (1/751) 0.070
Any 1.2% (9/760) 0.4% (3/756) 0.144 1.3% (10/754) 0.5% (4/751) 0.178
Target lesion revascularization 4.1% (31/760) 2.6% (20/756) 0.154 4.5% (34/754) 3.2% (24/751) 0.228
Target vessel revascularization 5.4% (41/760) 4.9% (37/756) 0.728 6.2% (47/754) 6.8% (51/751) 0.677
Nontarget lesion, target vessel revascularization 2.0% (15/760) 2.8% (21/756) 0.317 2.5% (19/754) 4.3% (32/751) 0.065
Target vessel failure 6.6% (50/760) 7.1% (54/756) 0.685 7.7% (58/754) 9.6% (72/751) 0.200
Major adverse cardiac events 5.5% (42/760) 5.6% (42/756) 1.000 6.5% (49/754) 6.7% (50/751) 0.918alues are presented as % (n/total).
Abbreviations as in Tables 1 and 5.
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hrombosis among the treatment cohorts, there was a
rend toward more frequent protocol definition and ARC
A
B
C
Figure 2 Cumulative Incidence of Target Vessel Failure, Cardia
Myocardial Infarction, and TVR at 360 Days (ZES vs.
Time-to-event curves through 1 year for target vessel failure (A), cardiac death or
treated with zotarolimus-eluting stent (ZES) versus paclitaxel-eluting stent (PES). E
test. CI  confidence interval; HR  hazard ratio.efinition (definite or probable) stent thrombosis with dES compared with PES at 9- and 12-month follow-up
Table 6). Of the 7 ZES patients with ARC stent
hrombosis (definite or probable), 3 occurred before 30
th and
rdial infarction (MI) (B), and target vessel revascularization (TVR) (C) in patients
tes represent Kaplan-Meier estimates. The p values are based on the log-rankc Dea
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ZES patients with ARC definite or probable stent
hrombosis before 30 days, 2 were associated with edge
issection and incomplete stent expansion and 1 had an
nplanned surgical procedure. In the 4 ZES patients with
RC definite or probable stent thrombosis between 30
ays and 6 months, 3 patients were no longer taking
APT (time of DAPT cessation to stent thrombosis was
days, 20 days, and 2 months), 1 of which also had an
nplanned surgical procedure.
There were no differences in overall clinically driven TLR or
VR comparing ZES with PES at either 9- or 12-month
ollow-up (Table 6, Fig. 2C). In those patients with angio-
raphic follow-up (18% of the total study population), TLR at
2 months was 8.5% for ZES and 3.0% for PES (p  0.071)
Fig. 3). In those patients without angiographic follow-up
82% of the study population), TLR was 3.6% for ZES and
.2% for PES (p  0.756) (Fig. 3).
ubgroup analysis and predictors of TLR. Analyses of
linical subgroups emphasizing high restenosis-risk patients
evealed no significant differences (nonsignificant interaction p
alues) between ZES and PES at 1-year clinical follow-up for
ither TVF or TVR (Figs. 4A and 4B).
Multivariate predictors of TLR at 12 months for
ll patients were history of diabetes, left anterior des-
ending target vessel and the presence of multiple stents
Table 7). A history of diabetes, multiple stents, and
ge were significant predictors of TLR for the PES
roup. The only significant predictor of TLR for patients
n the ZES group was assignment to angiographic
ollow-up.
iscussion
he main findings from the randomized ENDEAVOR
V study comparing ZES versus PES in patients with
imple and medium complexity single de novo coronary
Figure 3 TLR at 12 Months for Angiographic
and Nonangiographic Follow-Up Subgroups
Rates of target lesion revascularization (TLR) at 12 months in patients
with and without angiographic follow-up treated with ZES versus PES. Abbre-
viations as in Figure 2.esions are: f. The primary clinical end point, 9-month TVF, was
similar in ZES and PES patients.
. The powered secondary end point was not met in this
study with in-segment late lumen loss being significantly
higher in ZES versus PES patients.
. Despite the less robust reduction in intimal hyperplasia
seen on angiography with ZES versus PES, the clinical
expression of restenosis (TLR and TVR) were similar
among the 2 study cohorts after 9- and 12-month
follow-up.
The primary clinical end point, 9-month TVF, which
ncludes both safety and efficacy measures, was very close
n ZES and PES patients (6.6% and 7.1%, respectively,
noninferiority  0.001). Individual safety end points such
s cardiac death and MI were also similar in the 2 groups,
hough non–Q-wave MIs were still more frequent in PES
atients (19 vs. 10 events; p  0.095), undoubtedly a
eflection of the earlier increase in periprocedural non–
-wave MIs after PES treatment. Similar reduction in
eriprocedural non–Q-wave MIs was observed when
ES was compared with SES in a smaller randomized
rial (from 3.5% with SES to 0.6% with ZES, p  0.042)
16). Importantly, in ENDEAVOR IV, of the 17
eriprocedural non–Q-wave MIs after PES, 8 (47%) were
arge MIs with 10 upper limit of normal creatine
inase-myocardial band rises. Other studies have indi-
ated a higher than expected frequency of periprocedural
Is associated with PES implantation with a reported
ncidence of 3.5% to 5.4% (2,3) and post hoc angio-
raphic analyses have suggested that disproportionate
hanges in PES covered side branches (both occlusion
nd/or reduced flow) may be partially responsible for
hese early clinical events (3,24).
During the 12-month follow-up, there was an increase
n both protocol-defined and ARC-defined stent throm-
osis after ZES therapy, which although not significant,
equires further comment. Early stent thrombosis (within
0 days of the procedure) for both bare-metal stents and
ES is usually influenced by anatomic, procedural, and
linical factors (25). Of the 7 ARC definite or probable
ES thrombosis events, 3 occurred within 30 days and all
ere associated procedural mishaps (edge dissection or
ncomplete stent expansion) or clinical comorbid situa-
ions (unplanned surgery). The remaining 4 ZES throm-
osis events occurred between 1 and 6 months, and in 3
atients, clopidogrel therapy was discontinued before the
vent, and 1 of these patients also had unplanned surgery
mmediately before the event. Study-to-study variations
n stent thrombosis within the first year of follow-up are
ommonly observed among DES trials and the frequency
f stent thrombosis for ZES in this trial was greater than
eported in previous studies (13,15,16,26,27), whereas
he stent thrombosis rates for PES in this trial were lower
han previously reported (2,3,28). Such variations in the
ncidence of stent thrombosis during the first year of
ollow-up are exemplified in the reports from 2 recent
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omparing the safety and efficacy of SES versus PES
SORT OUT II [Comparison of Paclitaxel- and
irolimus-Eluting Stents in Everyday Clinical Practice]
rial) (29) or ZES (SORT OUT III [Comparison of
otarolimus-Eluting Stents and Sirolimus-Eluting
tents in Patients with Coronary Artery Disease] trial)
A
B
Figure 4 Subgroup Analyses of the 1-Year Rates of TVF and TV
Subgroup analyses of the 1-year target vessel failure (TVF) (A) and TVR (B) among
sents the likelihood for interaction between the variable and the relative treatmen30) in a real-world study population. The rates of pefinite stent thrombosis at 9 months in patients ran-
omized to SES were unusually low in SORT OUT III
0.2%) and considerably higher in SORT OUT II (1.7%),
espite similar methodology and patient populations.
mportantly, DES safety has usually been associated with
ncreased stent thrombosis events occurring longer than 1
ear after the index procedure. Therefore, long-term
S vs. PES)
atients randomized to receive a ZES versus PES. Probability for interaction repre-
t. LAD  left anterior descending artery; other abbreviations as in Figure 2.R (ZE
the p
t effecatient follow-up from the ENDEAVOR IV trial is
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February 9, 2010:543–54 12-Month Outcomes From the ENDEAVOR IV Trialequired to determine if the frequency of very late stent
hrombosis is impacted by ZES therapy. Moreover, the
ngoing PROTECT (Patient Related OuTcomes with
ndeavor versus Cypher stenting Trial), the largest
andomized trial focusing on the comparative safety of
ES (n  8,800) will assess rates of stent thrombosis in
atients assigned to SES versus ZES after 3 years of
linical follow-up (31).
Angiographic follow-up, performed at 8 months after
he index procedure in 18% of the patients indicated
ignificantly lower in-segment minimum lumen diameter,
higher in-segment percent diameter stenosis, and a
igher in-segment late loss with ZES compared with
ES. The angiographic follow-up findings after ZES in
his study were comparable to multiple other ZES clinical
rials, which have shown a consistent in-stent late loss of
pproximately 0.60 mm (13,15,16,26). Although in-
egment binary restenosis was higher with ZES than with
ES (15.3% vs. 10.4%), the difference was not statisti-
ally significant (p  0.284). The rates of in-segment
estenosis in the PES arm in this study are somewhat
igher than in the PES arm in the pivotal TAXUS IV
rial (8.6%) and lower than in PES arm in the TAXUS V
rial (18.9%), which likely corresponds to the different
omplexity of treated lesions (2,3).
Despite the less robust reduction in intimal hyperplasia
een on angiography with ZES versus PES, the clinical
xpression of restenosis (TLR and TVR) were similar
ultivariate Predictorsf TLR and TVF at 12 MonthsTable 7 Multivariate Predictorsof TLR and TVF at 12 Months
Odds Ratio (95% CI) p Value
TLR predictors
All patients
History of diabetes 2.63 (1.50–4.64) 0.001
LAD (vs. all others) 2.03 (1.15–3.57) 0.014
Multiple vs. single stents 3.31 (1.59–6.89) 0.001
ZES patients
Angiographic follow-up vs.
clinical follow-up
2.88 (1.36–6.09) 0.006
PES patients
Age (yrs) 1.06 (1.02–1.11) 0.010
History of diabetes 3.73 (1.50–9.26) 0.005
Multiple vs. single stents 4.33 (1.57–11.96) 0.005
TVF predictors
All patients
History of hyperlipidemia 0.53 (0.29–0.98) 0.044
Multiple vs. single stents 1.82 (1.24–2.66) 0.002
ZES patients
Multiple vs. single stents 2.38 (1.00–5.67) 0.049
Pre-diameter stenosis, % 1.03 (1.01–1.05) 0.016
PES patients
Age (yrs) 1.03 (1.00–1.05) 0.036
History of prior MI 0.52 (0.30–0.89) 0.018
Multiple vs. single stents 3.11 (1.63–5.92) 0.001
I confidence interval; LAD left anterior descending; MImyocardial infarction; TLR target
esion revascularization; TVF  target vessel failure; other abbreviations as in Table 1.mong the 2 study cohorts after 9- and 12-month Pollow-up both in the entire trial population and in high
estenosis subgroups (including diabetics, longer lesions,
maller vessels, and multiple stent cases). The most likely
xplanation for the disparity between ZES versus PES
ifferences in rates of angiographic and clinical restenosis
s the remarkable influence of routine angiographic
ollow-up examinations on the frequency repeat revascu-
arization events known as “oculo-stenotic reflex” (32). In
his study, there was more than a 2-fold higher frequency
f TLR after ZES in those patients with versus those
ithout systematic angiographic follow-up. The higher
ate loss after ZES, eliciting many situations in which the
isual estimate of follow-up angiographic diameter ste-
osis approaches or exceeds 50%, likely heightens this
endency. Further confirmation is derived from the mul-
ivariable analysis, wherein unlike PES, the only multi-
ariable predictor of TLR after ZES was assignment to
outine angiographic follow-up.
tudy limitations. As with most pivotal early stage ran-
omized clinical trials used for Food and Drug Admin-
stration approval of a DES in the U.S. (1,2,4,17), the
esion and patient inclusion criteria for ENDEAVOR IV
re somewhat restrictive. Thus, the reported findings can
nly be applied to the simple-to-medium complexity
esions and stable patients that were treated. This study
as designed to test the noninferiority of ZES versus
ES for TVF and in-segment late loss; the p values for all
he other end points should be viewed with caution.
efinitive conclusions regarding ZES safety, especially
ery late stent thrombosis, will necessitate prolonged
linical follow-up for several additional years. In addi-
ion, the trial was not specifically powered to evaluate the
ifferences in rates of individual clinical end points
ncluding MI and TLR, and therefore these results
hould be viewed as hypothesis-generating rather than
efinitive.
onclusions
he ENDEAVOR IV trial should be viewed as a
omponent of the larger comprehensive assessment of the
ew Endeavor ZES. Compared with the well-
haracterized PES, findings from this randomized trial
ndicate that in single de novo coronary lesions, the
ndeavor ZES has improved periprocedural safety, sim-
lar 12-month clinical safety and efficacy outcomes, and
espite more frequent angiographic restenosis, similar
linical repeat revascularization events.
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